Related Experiment Video
Updated: Apr 20, 2026
07:57
An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
7.5K
[Pathogenesis of the basal forebrain cholinergic dysfunction in Alzheimer's disease]
Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova
|December 5, 2014
Summary
Alzheimer's disease, a leading cause of dementia, involves cholinergic dysfunction. This review summarizes current knowledge on the pathogenesis of cholinergic deficits in Alzheimer's disease.
Area of Science:
- Neuroscience
- Pathology
- Biochemistry
Context:
- Alzheimer's disease (AD) is the most prevalent cause of dementia, characterized by neurodegeneration.
- Key pathogenetic components include cholinergic dysfunction, synaptic plasticity impairment, and neuronal death.
- Understanding these components is crucial for developing effective AD treatments.
Purpose:
- To review and synthesize current literature on the pathogenesis of cholinergic dysfunction in Alzheimer's disease.
- To provide a comprehensive overview of the first major pathogenetic component of AD.
Summary:
- This review consolidates data on cholinergic dysfunction, a primary factor in Alzheimer's disease pathogenesis.
- It details the current understanding of how cholinergic systems are impaired in AD.
- Focuses on the neurobiological mechanisms underlying cholinergic deficits.
Impact:
- Provides a foundational resource for researchers studying Alzheimer's disease.
- Highlights the critical role of cholinergic pathways in AD pathology.
- Informs future therapeutic strategies targeting cholinergic dysfunction in dementia.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
2
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
2
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:29Alzheimer Disease l: Introduction
4
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
4
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:24Parkinson Disease ll: Pathophysiology
6
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
6
01:22Dementia l: Introduction
3
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
3